Adma Biologics (ADMA) Net Cash Flow Growth (1y) (2012 - 2025)
Adma Biologics (ADMA) Net Cash Flow Growth (1y) (2012 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 301.06% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn | 59.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 59.64% |
| Sep 30, 2025 | -1,780.29% |
| Jun 30, 2025 | -56.52% |
| Mar 31, 2025 | -423.01% |
| Dec 31, 2024 | 172.09% |
| Sep 30, 2024 | -113.20% |
| Jun 30, 2024 | 741.44% |
| Mar 31, 2024 | 65.20% |
| Dec 31, 2023 | -144.18% |
| Sep 30, 2023 | 166.50% |
| Jun 30, 2023 | 60.85% |
| Mar 31, 2023 | -194.04% |
| Dec 31, 2022 | 209.48% |
| Sep 30, 2022 | -118.91% |
| Jun 30, 2022 | 12.61% |
| Mar 31, 2022 | 204.67% |
| Dec 31, 2021 | 544.30% |
| Sep 30, 2021 | 50.34% |
| Jun 30, 2021 | 23.17% |
| Mar 31, 2021 | -91.88% |